Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2025-12-17 @ 8:13 AM
Study NCT ID:
NCT06450041
Status:
None
Last Update Posted:
2025-11-04 00:00:00
First Post:
2024-05-31 00:00:00
Brief Title:
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Sponsor:
Organization:
New Approaches to Neuroblastoma Therapy Consortium
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
62
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: